Innospec（OCT）株式概要イノスペック社は、アメリカ大陸、ヨーロッパ、中東、アフリカ、アジア太平洋地域で特殊化学品の開発、製造、ブレンド、販売、供給を行っている。 詳細OCT ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長2/6過去の実績4/6財務の健全性6/6配当金5/6報酬当社が推定した公正価値より28.6%で取引されている 収益は年間14.83%増加すると予測されています 過去1年間で収益は323%増加しました 2.09%の安定した配当金を支払う 同業他社や業界と比較して、良好な取引価格 リスク分析リスクチェックの結果、OCT 、リスクは検出されなかった。すべてのリスクチェックを見るOCT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€71.0012.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture03b2016201920222025202620282031Revenue US$2.5bEarnings US$160.7mAdvancedSet Fair ValueView all narrativesInnospec Inc. 競合他社AlzChem GroupSymbol: XTRA:ACTMarket cap: €1.9bEvonik IndustriesSymbol: XTRA:EVKMarket cap: €7.4bSymriseSymbol: XTRA:SY1Market cap: €11.5bUzin UtzSymbol: XTRA:UZUMarket cap: €317.8m価格と性能株価の高値、安値、推移の概要Innospec過去の株価現在の株価US$71.0052週高値US$76.5052週安値US$56.00ベータ0.911ヶ月の変化5.19%3ヶ月変化22.41%1年変化0%3年間の変化-21.11%5年間の変化-8.39%IPOからの変化294.66%最新ニュースお知らせ • Jun 05Innospec Inc. Announces Appointment of Shelley Bausch as Director and Audit Committee Member, Effective July 1, 2026Innospec Inc. had increased the number of directors of the Company from seven to eight, and appointed Shelley Bausch to serve as a Class II director of the Company starting as of July 1, 2026, and until the 2027 annual meeting of stockholders of the Company or until her successor is duly elected and qualified. Ms. Bausch was also appointed to serve on the Company's Audit Committee as of July 1, 2026.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 10Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026.お知らせ • May 08Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock.お知らせ • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026お知らせ • Mar 27Innospec Inc., Annual General Meeting, May 08, 2026Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United States最新情報をもっと見るRecent updatesお知らせ • Jun 05Innospec Inc. Announces Appointment of Shelley Bausch as Director and Audit Committee Member, Effective July 1, 2026Innospec Inc. had increased the number of directors of the Company from seven to eight, and appointed Shelley Bausch to serve as a Class II director of the Company starting as of July 1, 2026, and until the 2027 annual meeting of stockholders of the Company or until her successor is duly elected and qualified. Ms. Bausch was also appointed to serve on the Company's Audit Committee as of July 1, 2026.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 10Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026.お知らせ • May 08Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock.お知らせ • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026お知らせ • Mar 27Innospec Inc., Annual General Meeting, May 08, 2026Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United Statesお知らせ • Jan 12Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026お知らせ • Nov 05Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2025, Payable on November 26, 2025Innospec Inc. declared a semi-annual dividend of 87 cents per common share for the second half of 2025, which will be paid on November 26, 2025 to shareholders of record as of November 18, 2025.お知らせ • Oct 02Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025お知らせ • Jul 03Innospec Inc. to Report Q2, 2025 Results on Aug 05, 2025Innospec Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025お知らせ • May 09Innospec Inc. Declares Semi-Annual Dividend, Payable on May 30, 2025Innospec Inc. declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 30, 2025 to shareholders of record on May 20, 2025.お知らせ • Apr 04Innospec Inc. to Report Q1, 2025 Results on May 08, 2025Innospec Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025お知らせ • Mar 28Innospec Inc., Annual General Meeting, May 09, 2025Innospec Inc., Annual General Meeting, May 09, 2025. Location: westin at the woodlands hotel, 2 waterway square place, the woodlands, houston tx 77380, United Statesお知らせ • Mar 11Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock.お知らせ • Jan 09Innospec Inc. to Report Q4, 2024 Results on Feb 18, 2025Innospec Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025Declared Dividend • Nov 11Dividend of US$0.79 announcedShareholders will receive a dividend of US$0.79. Ex-date: 18th November 2024 Payment date: 26th November 2024 Dividend yield will be 1.3%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Nov 06Third quarter 2024 earnings released: EPS: US$1.34 (vs US$1.58 in 3Q 2023)Third quarter 2024 results: EPS: US$1.34 (down from US$1.58 in 3Q 2023). Revenue: US$443.4m (down 4.5% from 3Q 2023). Net income: US$33.4m (down 15% from 3Q 2023). Profit margin: 7.5% (down from 8.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 04Innospec Inc. to Report Q3, 2024 Results on Nov 06, 2024Innospec Inc. announced that they will report Q3, 2024 results on Nov 06, 2024Recent Insider Transactions • Aug 29Executive VP & CFO recently sold €1.0m worth of stockOn the 26th of August, Ian Cleminson sold around 10k shares on-market at roughly €102 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by €1.5m.Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: US$1.25 (vs US$1.16 in 2Q 2023)Second quarter 2024 results: EPS: US$1.25 (up from US$1.16 in 2Q 2023). Revenue: US$435.0m (down 9.5% from 2Q 2023). Net income: US$31.2m (up 8.0% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Jul 17Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 6.3% to €118. The fair value is estimated to be €96.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.0% in a year. Earnings are forecast to grow by 11% in the next year.お知らせ • Jul 04Innospec Inc. to Report Q2, 2024 Results on Aug 06, 2024Innospec Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024Buy Or Sell Opportunity • Jun 04Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.3% to €119. The fair value is estimated to be €98.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.7% in a year. Earnings are forecast to grow by 12% in the next year.Buy Or Sell Opportunity • May 12Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 8.9% to €122. The fair value is estimated to be €98.86, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 5.6% in a year. Earnings are forecast to grow by 12% in the next year.お知らせ • May 11Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2024Innospec Inc. declared its semi-annual dividend of 76 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 31, 2024 to shareholders of record on May 20, 2024.Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.34 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.34 in 1Q 2023). Revenue: US$500.2m (down 1.8% from 1Q 2023). Net income: US$41.4m (up 25% from 1Q 2023). Profit margin: 8.3% (up from 6.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Apr 10Now 20% undervaluedOver the last 90 days, the stock has risen 9.6% to €114. The fair value is estimated to be €143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 7.9% in 2 years. Earnings are forecast to grow by 25% in the next 2 years.お知らせ • Apr 06Innospec Inc. to Report Q1, 2024 Results on May 09, 2024Innospec Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024お知らせ • Apr 03Innospec Inc. Announces Retirement of Philip Boon, Executive Vice President and Chief Operating Officer Effective March 31, 2025On March 31, 2024, Dr. Philip Boon, Executive Vice President and Chief Operating Officer of Innospec Inc. (the “Company”), informed the Company of his decision to officially retire effective March 31, 2025. Dr. Boon will provide various support to the Company on a consultancy basis, on terms to be agreed, after his retirement.お知らせ • Mar 29Innospec Inc., Annual General Meeting, May 10, 2024Innospec Inc., Annual General Meeting, May 10, 2024, at 10:00 US Eastern Standard Time. Location: The offices of Smith, Gambrell & Russell LLP 1105 West Peachtree Street NE suite 1000 Atlanta Georgia United States Agenda: To consider election of two Class II Directors; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm; and to discuss other matters.Recent Insider Transactions • Mar 08Senior VP recently sold €290k worth of stockOn the 1st of March, David Jones sold around 3k shares on-market at roughly €116 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €1.1m. Insiders have been net sellers, collectively disposing of €4.7m more than they bought in the last 12 months.Recent Insider Transactions • Feb 28President recently sold €1.1m worth of stockOn the 23rd of February, Patrick Williams sold around 10k shares on-market at roughly €115 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Patrick has been a net seller over the last 12 months, reducing personal holdings by €4.0m.Reported Earnings • Feb 14Full year 2023 earnings released: EPS: US$5.60 (vs US$5.37 in FY 2022)Full year 2023 results: EPS: US$5.60 (up from US$5.37 in FY 2022). Revenue: US$1.95b (flat on FY 2022). Net income: US$139.1m (up 4.6% from FY 2022). Profit margin: 7.1% (up from 6.8% in FY 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 2 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.お知らせ • Dec 12Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A.Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. on December 8, 2023. Innospec will integrate QGP into its Performance Chemicals business. Innospec Inc. (NasdaqGS:IOSP) completed the acquisition of QGP Química Geral S.A. on December 8, 2023.Board Change • Dec 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.56 in 3Q 2022)Third quarter 2023 results: EPS: US$1.58 (up from US$1.56 in 3Q 2022). Revenue: US$464.1m (down 9.5% from 3Q 2022). Net income: US$39.2m (up 1.3% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 08Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2023, Payable on November 27, 2023Innospec Inc. announced that it has declared a semi-annual dividend of 72 cents per common share for the second half of 2023 which will be paid on November 27, 2023 to shareholders of record as of November 20, 2023. This brings the annual dividend to $1.41 per share, a 10 percent increase over 2022.お知らせ • Aug 13Innospec Inc. to Report Q3, 2023 Results on Nov 07, 2023Innospec Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 07, 2023Reported Earnings • Aug 09Second quarter 2023 earnings released: EPS: US$1.16 (vs US$1.30 in 2Q 2022)Second quarter 2023 results: EPS: US$1.16 (down from US$1.30 in 2Q 2022). Revenue: US$480.4m (up 2.7% from 2Q 2022). Net income: US$28.9m (down 11% from 2Q 2022). Profit margin: 6.0% (down from 6.9% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 2 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 07Innospec Inc. to Report Q2, 2023 Results on Aug 08, 2023Innospec Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023Upcoming Dividend • May 12Upcoming dividend of US$0.69 per share at 1.4% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.6%).お知らせ • May 05Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2023Innospec Inc. declared a semi-annual dividend of $0.69 per share on the Company’s common stock (IOSP). The dividend will be paid on May 31, 2023 to holders of record on May 22, 2023.Reported Earnings • May 04First quarter 2023 earnings released: EPS: US$1.34 (vs US$1.47 in 1Q 2022)First quarter 2023 results: EPS: US$1.34 (down from US$1.47 in 1Q 2022). Revenue: US$509.6m (up 7.9% from 1Q 2022). Net income: US$33.2m (down 9.0% from 1Q 2022). Profit margin: 6.5% (down from 7.7% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Mar 03President recently sold €1.9m worth of stockOn the 28th of February, Patrick Williams sold around 18k shares on-market at roughly €104 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months.Reported Earnings • Feb 23Full year 2022 earnings released: EPS: US$5.37 (vs US$3.78 in FY 2021)Full year 2022 results: EPS: US$5.37 (up from US$3.78 in FY 2021). Revenue: US$1.96b (up 32% from FY 2021). Net income: US$133.0m (up 43% from FY 2021). Profit margin: 6.8% (up from 6.3% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 11Innospec Inc. to Report Q4, 2022 Results on Feb 21, 2023Innospec Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2023Recent Insider Transactions • Dec 07Senior VP recently bought €77k worth of stockOn the 5th of December, David Jones bought around 752 shares on-market at roughly €103 per share. This transaction amounted to 97% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €610k more in shares than they bought in the last 12 months.Reported Earnings • Nov 10Third quarter 2022 earnings released: EPS: US$1.56 (vs US$0.95 in 3Q 2021)Third quarter 2022 results: EPS: US$1.56 (up from US$0.95 in 3Q 2021). Revenue: US$513.0m (up 36% from 3Q 2021). Net income: US$38.7m (up 65% from 3Q 2021). Profit margin: 7.5% (up from 6.2% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.3% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 09Innospec Inc. Declares Semi-Annual Dividend, Payable on November 28, 2022Innospec Inc. announced that it has declared a semi-annual dividend of 65 cents per common share for the second half of 2022 which will be paid on November 28, 2022 to shareholders of record as of November 21, 2022. This brings the annual dividend to $1.28 per share, a 10% increase over 2021.お知らせ • Oct 07Innospec Inc. to Report Q3, 2022 Results on Nov 08, 2022Innospec Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 08, 2022Reported Earnings • Aug 03Second quarter 2022 earnings released: EPS: US$1.30 (vs US$0.91 in 2Q 2021)Second quarter 2022 results: EPS: US$1.30 (up from US$0.91 in 2Q 2021). Revenue: US$467.6m (up 32% from 2Q 2021). Net income: US$32.3m (up 44% from 2Q 2021). Profit margin: 6.9% (up from 6.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.7%, compared to a 6.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 8% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 08Innospec Inc. to Report Q2, 2022 Results on Aug 02, 2022Innospec Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 02, 2022Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to €89.50, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 8x in the Chemicals industry in Germany. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €40.04 per share.Reported Earnings • May 05First quarter 2022 earnings released: EPS: US$1.47 (vs US$0.95 in 1Q 2021)First quarter 2022 results: EPS: US$1.47 (up from US$0.95 in 1Q 2021). Revenue: US$472.4m (up 39% from 1Q 2021). Net income: US$36.5m (up 56% from 1Q 2021). Profit margin: 7.7% (up from 6.9% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.5%, compared to a 8.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • May 05Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2022, Payable on May 26, 2022Innospec Inc. announced the declaration of its semi-annual dividend of 63 cents per common share for the first half of 2022, representing an increase of 11% This dividend will be paid on May 26, 2022, to shareholders of record on May 17, 2022.お知らせ • Apr 07Innospec Inc. to Report Q1, 2022 Results on May 03, 2022Innospec Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022Recent Insider Transactions • Mar 04President recently sold €601k worth of stockOn the 25th of February, Patrick Williams sold around 7k shares on-market at roughly €85.90 per share. This was the largest sale by an insider in the last 3 months. Patrick has been a seller over the last 12 months, reducing personal holdings by €2.2m.お知らせ • Feb 18Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The program will run over the next three years from commencement date.Reported Earnings • Feb 16Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: US$3.78 (up from US$1.17 in FY 2020). Revenue: US$1.48b (up 24% from FY 2020). Net income: US$93.1m (up 224% from FY 2020). Profit margin: 6.3% (up from 2.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 5.2%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Jan 06Innospec Secures China Approval for Its Ultra-Mild, Sulfate-Free Iselux® SurfactantsInnospec announces that Iselux® has been approved for use in China, the world’s second large personal care market. Available in liquid and solid form, Iselux® is a highly versatile, clear, mild and natural surfactant which delivers superior lather, skin feel and cleansing performance in more than 3,000 body, hair and other personal care products today. With the China approval secured, for the first time Iselux® is now available for worldwide cosmetic and personal care use by Innospec’s customers. Innospec technologies like Iselux® directly address growing long-term consumer demand for clean beauty without any compromise in product performance. Innospec recently announced plans for over $70MM of organic growth investments to be made through 2023 to support the increased demand outlook for its premium personal and home care technologies.Recent Insider Transactions • Nov 15President recently sold €968k worth of stockOn the 9th of November, Patrick Williams sold around 12k shares on-market at roughly €80.67 per share. This was the largest sale by an insider in the last 3 months. Patrick has been a seller over the last 12 months, reducing personal holdings by €1.6m.Reported Earnings • Nov 04Third quarter 2021 earnings released: EPS US$0.95 (vs US$0.52 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$376.1m (up 42% from 3Q 2020). Net income: US$23.4m (up 84% from 3Q 2020). Profit margin: 6.2% (up from 4.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • Aug 04Second quarter 2021 earnings released: EPS US$0.91 (vs US$1.62 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$354.5m (up 45% from 2Q 2020). Net income: US$22.4m (up US$62.1m from 2Q 2020). Profit margin: 6.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Recent Insider Transactions • May 13President recently sold €382k worth of stockOn the 7th of May, Patrick Williams sold around 5k shares on-market at roughly €83.67 per share. This was the largest sale by an insider in the last 3 months. Patrick has been a seller over the last 12 months, reducing personal holdings by €928k.Reported Earnings • May 06First quarter 2021 earnings released: EPS US$0.95 (vs US$1.35 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$339.6m (down 8.8% from 1Q 2020). Net income: US$23.4m (down 29% from 1Q 2020). Profit margin: 6.9% (down from 8.9% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • May 05Innospec Inc. Announces Semi-Annual Dividend for the First Half of 2021, Payable on May 26, 2021Innospec Inc. announced the declaration of its semi-annual dividend of $0.57 per common share for the first half of 2021, representing an increase of 10%. This dividend will be paid on May 26, 2021, to shareholders of record on May 17, 2021.Executive Departure • May 04Senior Vice President of Corporate Development & Investor Relations Brian Watt has left the companyOn the 30th of April, Brian Watt's tenure as Senior Vice President of Corporate Development & Investor Relations ended after 3.7 years in the role. We don't have any record of a personal shareholding under Brian's name. A total of 2 executives have left over the last 12 months.お知らせ • Mar 20Innospec Inc., Annual General Meeting, May 05, 2021Innospec Inc., Annual General Meeting, May 05, 2021, at 10:00 US Eastern Standard Time. Agenda: To consider election of two Class II Directors; to consider ratification of the election of one Class I Director; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm.Is New 90 Day High Low • Feb 26New 90-day high: €84.00The company is up 17% from its price of €71.50 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period.お知らせ • Feb 26Brian Watt Informs His Decision to Retire as Senior Vice President, Corporate Development and Investor Relations of Innospec Inc., Effective April 30, 2021On February 23, 2021, Mr. Brian Watt, Senior Vice President, Corporate Development and Investor Relations of Innospec Inc. (the 'Company'), informed the Company of his decision to officially retire effective April 30, 2021. The Company is discussing with Mr. Watt the possibility of him providing various support after his retirement.Reported Earnings • Feb 19Full year 2020 earnings released: EPS US$1.17 (vs US$4.58 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$1.19b (down 21% from FY 2019). Net income: US$28.7m (down 74% from FY 2019). Profit margin: 2.4% (down from 7.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 19Revenue beats expectationsRevenue exceeded analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 9.4%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.お知らせ • Jan 19Innospec Inc. to Report Q4, 2020 Results on Feb 16, 2021Innospec Inc. announced that they will report Q4, 2020 results After-Market on Feb 16, 2021Valuation Update With 7 Day Price Move • Jan 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$83.00, the stock is trading at a trailing P/E ratio of 66.3x, up from the previous P/E ratio of 57.1x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 45%.Is New 90 Day High Low • Jan 08New 90-day high: €78.00The company is up 37% from its price of €57.00 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €26.34 per share.Is New 90 Day High Low • Dec 19New 90-day high: €73.50The company is up 30% from its price of €56.50 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.44 per share.Valuation Update With 7 Day Price Move • Nov 26Market bids up stock over the past weekAfter last week's 17% share price gain to US$72.00, the stock is trading at a trailing P/E ratio of 57.7x, up from the previous P/E ratio of 49.3x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 24%.Is New 90 Day High Low • Nov 16New 90-day high: €69.00The company is up 10.0% from its price of €63.00 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €130 per share.Valuation Update With 7 Day Price Move • Nov 16Market bids up stock over the past weekAfter last week's 19% share price gain to US$69.00, the stock is trading at a trailing P/E ratio of 52.7x, up from the previous P/E ratio of 44.3x. This compares to an average P/E of 26x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 24%.Upcoming Dividend • Nov 09Upcoming Dividend of US$0.52 Per ShareWill be paid on the 25th of November to those who are registered shareholders by the 16th of November. The trailing yield of 1.5% is below the top quartile of German dividend payers (3.8%), and is lower than industry peers (4.4%).Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS US$0.52The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$265.1m (down 29% from 3Q 2019). Net income: US$12.7m (down 58% from 3Q 2019). Profit margin: 4.8% (down from 8.1% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 2% per year and the company’s share price has also increased by 2% per year.Analyst Estimate Surprise Post Earnings • Nov 05Revenue misses expectationsRevenue missed analyst estimates by 4.5%. Over the next year, revenue is forecast to grow 4.6%, compared to a 2.3% growth forecast for the Chemicals industry in Germany.お知らせ • Nov 03Innospec Inc. Appoints Elizabeth Keller Arnold as A Non-Employee DirectorInnospec Inc. announced that it has appointed Ms Elizabeth Keller Arnold as a non-employee director, effective November 1, 2020. After a long and successful career with General Electric and Tyco, Ms. Arnold was most recently Chief Financial Officer of Houghton International, a highly regarded global specialty chemical company. She is also an independent director of FreightCar America Inc. She has been appointed for an initial term until the 2021 Annual Stockholders Meeting and will also become a member of the Audit Committee.お知らせ • Oct 08Innospec Inc. to Report Q3, 2020 Results on Nov 03, 2020Innospec Inc. announced that they will report Q3, 2020 results at 5:00 PM, GMT Standard Time on Nov 03, 2020Is New 90 Day High Low • Sep 25New 90-day low: €53.00The company is down 18% from its price of €64.50 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €120 per share.お知らせ • Jul 08Innospec Inc. to Report Q2, 2020 Results on Aug 04, 2020Innospec Inc. announced that they will report Q2, 2020 results at 5:00 PM, GMT Standard Time on Aug 04, 2020株主還元OCTDE ChemicalsDE 市場7D0.7%0.3%2.4%1Y0%4.1%5.0%株主還元を見る業界別リターン: OCT過去 1 年間で4.1 % の収益を上げたGerman Chemicals業界を下回りました。リターン対市場: OCTは、過去 1 年間で5 % のリターンを上げたGerman市場を下回りました。価格変動Is OCT's price volatile compared to industry and market?OCT volatilityOCT Average Weekly Movement3.8%Chemicals Industry Average Movement5.9%Market Average Movement5.9%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.8%安定した株価: OCT 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: OCTの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19382,450Patrick Williamsinnospec.comイノスペック社は、米州、欧州、中東、アフリカ、アジア太平洋地域で特殊化学品の開発、製造、混合、販売、供給を行っている。3つのセグメントで事業を展開：パフォーマンスケミカルズ、燃料スペシャリティーズ、油田サービス。同社は、ディーゼル燃料、ジェット燃料、船舶用燃料、燃料油、その他の燃料の添加剤として使用される特殊化学製品を提供しており、商業用トラック、船舶、航空エンジン、発電所、暖房油、その他の産業機械用途に使用されている。また、パーソナルケア、ホームケア、農薬、建設、鉱業、その他の産業市場において、顧客のプロセスや製品に革新的な技術に基づくソリューションを提供している。さらに、掘削、完成、生産、DRA、石油・ガス用途の化学ソリューションの開発・販売も行っている。大手多国籍企業、パーソナルケアおよびホームケア製品メーカー、世界的な鉱業、農業および建築製品メーカー、その他の産業企業、国営および多国籍石油会社、燃料販売業者および小売業者、燃料ターミナル、海上ライン、塗料およびプラスチック製造業者、その他の重工業エンドユーザー、多国籍の上場および独立系探鉱・生産、油田サービス企業にサービスを提供している。2006年1月に社名をInnospec Inc.に変更。は1938年に設立され、コロラド州エングルウッドに本社を置いている。もっと見るInnospec Inc. 基礎のまとめInnospec の収益と売上を時価総額と比較するとどうか。OCT 基礎統計学時価総額€1.79b収益（TTM）€99.37m売上高(TTM)€1.56b17.9xPER（株価収益率1.1xP/SレシオOCT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計OCT 損益計算書（TTM）収益US$1.79b売上原価US$1.30b売上総利益US$490.80mその他の費用US$376.60m収益US$114.20m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）4.64グロス・マージン27.41%純利益率6.38%有利子負債／自己資本比率0%OCT の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.1%現在の配当利回り37%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 04:34終値2026/06/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Innospec Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Jonathan TanwantengCJS Securities, Inc.David SilverFreedom Capital MarketsSean MilliganJohnson Rice & Company, L.L.C.4 その他のアナリストを表示
お知らせ • Jun 05Innospec Inc. Announces Appointment of Shelley Bausch as Director and Audit Committee Member, Effective July 1, 2026Innospec Inc. had increased the number of directors of the Company from seven to eight, and appointed Shelley Bausch to serve as a Class II director of the Company starting as of July 1, 2026, and until the 2027 annual meeting of stockholders of the Company or until her successor is duly elected and qualified. Ms. Bausch was also appointed to serve on the Company's Audit Committee as of July 1, 2026.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 10Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026.
お知らせ • May 08Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock.
お知らせ • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026
お知らせ • Mar 27Innospec Inc., Annual General Meeting, May 08, 2026Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United States
お知らせ • Jun 05Innospec Inc. Announces Appointment of Shelley Bausch as Director and Audit Committee Member, Effective July 1, 2026Innospec Inc. had increased the number of directors of the Company from seven to eight, and appointed Shelley Bausch to serve as a Class II director of the Company starting as of July 1, 2026, and until the 2027 annual meeting of stockholders of the Company or until her successor is duly elected and qualified. Ms. Bausch was also appointed to serve on the Company's Audit Committee as of July 1, 2026.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 10Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026.
お知らせ • May 08Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock.
お知らせ • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026
お知らせ • Mar 27Innospec Inc., Annual General Meeting, May 08, 2026Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United States
お知らせ • Jan 12Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026
お知らせ • Nov 05Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2025, Payable on November 26, 2025Innospec Inc. declared a semi-annual dividend of 87 cents per common share for the second half of 2025, which will be paid on November 26, 2025 to shareholders of record as of November 18, 2025.
お知らせ • Oct 02Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025
お知らせ • Jul 03Innospec Inc. to Report Q2, 2025 Results on Aug 05, 2025Innospec Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025
お知らせ • May 09Innospec Inc. Declares Semi-Annual Dividend, Payable on May 30, 2025Innospec Inc. declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 30, 2025 to shareholders of record on May 20, 2025.
お知らせ • Apr 04Innospec Inc. to Report Q1, 2025 Results on May 08, 2025Innospec Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025
お知らせ • Mar 28Innospec Inc., Annual General Meeting, May 09, 2025Innospec Inc., Annual General Meeting, May 09, 2025. Location: westin at the woodlands hotel, 2 waterway square place, the woodlands, houston tx 77380, United States
お知らせ • Mar 11Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock.
お知らせ • Jan 09Innospec Inc. to Report Q4, 2024 Results on Feb 18, 2025Innospec Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025
Declared Dividend • Nov 11Dividend of US$0.79 announcedShareholders will receive a dividend of US$0.79. Ex-date: 18th November 2024 Payment date: 26th November 2024 Dividend yield will be 1.3%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Nov 06Third quarter 2024 earnings released: EPS: US$1.34 (vs US$1.58 in 3Q 2023)Third quarter 2024 results: EPS: US$1.34 (down from US$1.58 in 3Q 2023). Revenue: US$443.4m (down 4.5% from 3Q 2023). Net income: US$33.4m (down 15% from 3Q 2023). Profit margin: 7.5% (down from 8.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 04Innospec Inc. to Report Q3, 2024 Results on Nov 06, 2024Innospec Inc. announced that they will report Q3, 2024 results on Nov 06, 2024
Recent Insider Transactions • Aug 29Executive VP & CFO recently sold €1.0m worth of stockOn the 26th of August, Ian Cleminson sold around 10k shares on-market at roughly €102 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by €1.5m.
Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: US$1.25 (vs US$1.16 in 2Q 2023)Second quarter 2024 results: EPS: US$1.25 (up from US$1.16 in 2Q 2023). Revenue: US$435.0m (down 9.5% from 2Q 2023). Net income: US$31.2m (up 8.0% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Jul 17Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 6.3% to €118. The fair value is estimated to be €96.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.0% in a year. Earnings are forecast to grow by 11% in the next year.
お知らせ • Jul 04Innospec Inc. to Report Q2, 2024 Results on Aug 06, 2024Innospec Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024
Buy Or Sell Opportunity • Jun 04Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.3% to €119. The fair value is estimated to be €98.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.7% in a year. Earnings are forecast to grow by 12% in the next year.
Buy Or Sell Opportunity • May 12Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 8.9% to €122. The fair value is estimated to be €98.86, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 5.6% in a year. Earnings are forecast to grow by 12% in the next year.
お知らせ • May 11Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2024Innospec Inc. declared its semi-annual dividend of 76 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 31, 2024 to shareholders of record on May 20, 2024.
Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.34 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.34 in 1Q 2023). Revenue: US$500.2m (down 1.8% from 1Q 2023). Net income: US$41.4m (up 25% from 1Q 2023). Profit margin: 8.3% (up from 6.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Apr 10Now 20% undervaluedOver the last 90 days, the stock has risen 9.6% to €114. The fair value is estimated to be €143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 7.9% in 2 years. Earnings are forecast to grow by 25% in the next 2 years.
お知らせ • Apr 06Innospec Inc. to Report Q1, 2024 Results on May 09, 2024Innospec Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024
お知らせ • Apr 03Innospec Inc. Announces Retirement of Philip Boon, Executive Vice President and Chief Operating Officer Effective March 31, 2025On March 31, 2024, Dr. Philip Boon, Executive Vice President and Chief Operating Officer of Innospec Inc. (the “Company”), informed the Company of his decision to officially retire effective March 31, 2025. Dr. Boon will provide various support to the Company on a consultancy basis, on terms to be agreed, after his retirement.
お知らせ • Mar 29Innospec Inc., Annual General Meeting, May 10, 2024Innospec Inc., Annual General Meeting, May 10, 2024, at 10:00 US Eastern Standard Time. Location: The offices of Smith, Gambrell & Russell LLP 1105 West Peachtree Street NE suite 1000 Atlanta Georgia United States Agenda: To consider election of two Class II Directors; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm; and to discuss other matters.
Recent Insider Transactions • Mar 08Senior VP recently sold €290k worth of stockOn the 1st of March, David Jones sold around 3k shares on-market at roughly €116 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €1.1m. Insiders have been net sellers, collectively disposing of €4.7m more than they bought in the last 12 months.
Recent Insider Transactions • Feb 28President recently sold €1.1m worth of stockOn the 23rd of February, Patrick Williams sold around 10k shares on-market at roughly €115 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Patrick has been a net seller over the last 12 months, reducing personal holdings by €4.0m.
Reported Earnings • Feb 14Full year 2023 earnings released: EPS: US$5.60 (vs US$5.37 in FY 2022)Full year 2023 results: EPS: US$5.60 (up from US$5.37 in FY 2022). Revenue: US$1.95b (flat on FY 2022). Net income: US$139.1m (up 4.6% from FY 2022). Profit margin: 7.1% (up from 6.8% in FY 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 2 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
お知らせ • Dec 12Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A.Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. on December 8, 2023. Innospec will integrate QGP into its Performance Chemicals business. Innospec Inc. (NasdaqGS:IOSP) completed the acquisition of QGP Química Geral S.A. on December 8, 2023.
Board Change • Dec 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.56 in 3Q 2022)Third quarter 2023 results: EPS: US$1.58 (up from US$1.56 in 3Q 2022). Revenue: US$464.1m (down 9.5% from 3Q 2022). Net income: US$39.2m (up 1.3% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 08Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2023, Payable on November 27, 2023Innospec Inc. announced that it has declared a semi-annual dividend of 72 cents per common share for the second half of 2023 which will be paid on November 27, 2023 to shareholders of record as of November 20, 2023. This brings the annual dividend to $1.41 per share, a 10 percent increase over 2022.
お知らせ • Aug 13Innospec Inc. to Report Q3, 2023 Results on Nov 07, 2023Innospec Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 07, 2023
Reported Earnings • Aug 09Second quarter 2023 earnings released: EPS: US$1.16 (vs US$1.30 in 2Q 2022)Second quarter 2023 results: EPS: US$1.16 (down from US$1.30 in 2Q 2022). Revenue: US$480.4m (up 2.7% from 2Q 2022). Net income: US$28.9m (down 11% from 2Q 2022). Profit margin: 6.0% (down from 6.9% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 2 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 07Innospec Inc. to Report Q2, 2023 Results on Aug 08, 2023Innospec Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023
Upcoming Dividend • May 12Upcoming dividend of US$0.69 per share at 1.4% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.6%).
お知らせ • May 05Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2023Innospec Inc. declared a semi-annual dividend of $0.69 per share on the Company’s common stock (IOSP). The dividend will be paid on May 31, 2023 to holders of record on May 22, 2023.
Reported Earnings • May 04First quarter 2023 earnings released: EPS: US$1.34 (vs US$1.47 in 1Q 2022)First quarter 2023 results: EPS: US$1.34 (down from US$1.47 in 1Q 2022). Revenue: US$509.6m (up 7.9% from 1Q 2022). Net income: US$33.2m (down 9.0% from 1Q 2022). Profit margin: 6.5% (down from 7.7% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Mar 03President recently sold €1.9m worth of stockOn the 28th of February, Patrick Williams sold around 18k shares on-market at roughly €104 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months.
Reported Earnings • Feb 23Full year 2022 earnings released: EPS: US$5.37 (vs US$3.78 in FY 2021)Full year 2022 results: EPS: US$5.37 (up from US$3.78 in FY 2021). Revenue: US$1.96b (up 32% from FY 2021). Net income: US$133.0m (up 43% from FY 2021). Profit margin: 6.8% (up from 6.3% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 11Innospec Inc. to Report Q4, 2022 Results on Feb 21, 2023Innospec Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2023
Recent Insider Transactions • Dec 07Senior VP recently bought €77k worth of stockOn the 5th of December, David Jones bought around 752 shares on-market at roughly €103 per share. This transaction amounted to 97% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €610k more in shares than they bought in the last 12 months.
Reported Earnings • Nov 10Third quarter 2022 earnings released: EPS: US$1.56 (vs US$0.95 in 3Q 2021)Third quarter 2022 results: EPS: US$1.56 (up from US$0.95 in 3Q 2021). Revenue: US$513.0m (up 36% from 3Q 2021). Net income: US$38.7m (up 65% from 3Q 2021). Profit margin: 7.5% (up from 6.2% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.3% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 09Innospec Inc. Declares Semi-Annual Dividend, Payable on November 28, 2022Innospec Inc. announced that it has declared a semi-annual dividend of 65 cents per common share for the second half of 2022 which will be paid on November 28, 2022 to shareholders of record as of November 21, 2022. This brings the annual dividend to $1.28 per share, a 10% increase over 2021.
お知らせ • Oct 07Innospec Inc. to Report Q3, 2022 Results on Nov 08, 2022Innospec Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 08, 2022
Reported Earnings • Aug 03Second quarter 2022 earnings released: EPS: US$1.30 (vs US$0.91 in 2Q 2021)Second quarter 2022 results: EPS: US$1.30 (up from US$0.91 in 2Q 2021). Revenue: US$467.6m (up 32% from 2Q 2021). Net income: US$32.3m (up 44% from 2Q 2021). Profit margin: 6.9% (up from 6.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.7%, compared to a 6.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 8% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 08Innospec Inc. to Report Q2, 2022 Results on Aug 02, 2022Innospec Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 02, 2022
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to €89.50, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 8x in the Chemicals industry in Germany. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €40.04 per share.
Reported Earnings • May 05First quarter 2022 earnings released: EPS: US$1.47 (vs US$0.95 in 1Q 2021)First quarter 2022 results: EPS: US$1.47 (up from US$0.95 in 1Q 2021). Revenue: US$472.4m (up 39% from 1Q 2021). Net income: US$36.5m (up 56% from 1Q 2021). Profit margin: 7.7% (up from 6.9% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.5%, compared to a 8.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • May 05Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2022, Payable on May 26, 2022Innospec Inc. announced the declaration of its semi-annual dividend of 63 cents per common share for the first half of 2022, representing an increase of 11% This dividend will be paid on May 26, 2022, to shareholders of record on May 17, 2022.
お知らせ • Apr 07Innospec Inc. to Report Q1, 2022 Results on May 03, 2022Innospec Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022
Recent Insider Transactions • Mar 04President recently sold €601k worth of stockOn the 25th of February, Patrick Williams sold around 7k shares on-market at roughly €85.90 per share. This was the largest sale by an insider in the last 3 months. Patrick has been a seller over the last 12 months, reducing personal holdings by €2.2m.
お知らせ • Feb 18Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The program will run over the next three years from commencement date.
Reported Earnings • Feb 16Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: US$3.78 (up from US$1.17 in FY 2020). Revenue: US$1.48b (up 24% from FY 2020). Net income: US$93.1m (up 224% from FY 2020). Profit margin: 6.3% (up from 2.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 5.2%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Jan 06Innospec Secures China Approval for Its Ultra-Mild, Sulfate-Free Iselux® SurfactantsInnospec announces that Iselux® has been approved for use in China, the world’s second large personal care market. Available in liquid and solid form, Iselux® is a highly versatile, clear, mild and natural surfactant which delivers superior lather, skin feel and cleansing performance in more than 3,000 body, hair and other personal care products today. With the China approval secured, for the first time Iselux® is now available for worldwide cosmetic and personal care use by Innospec’s customers. Innospec technologies like Iselux® directly address growing long-term consumer demand for clean beauty without any compromise in product performance. Innospec recently announced plans for over $70MM of organic growth investments to be made through 2023 to support the increased demand outlook for its premium personal and home care technologies.
Recent Insider Transactions • Nov 15President recently sold €968k worth of stockOn the 9th of November, Patrick Williams sold around 12k shares on-market at roughly €80.67 per share. This was the largest sale by an insider in the last 3 months. Patrick has been a seller over the last 12 months, reducing personal holdings by €1.6m.
Reported Earnings • Nov 04Third quarter 2021 earnings released: EPS US$0.95 (vs US$0.52 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$376.1m (up 42% from 3Q 2020). Net income: US$23.4m (up 84% from 3Q 2020). Profit margin: 6.2% (up from 4.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 04Second quarter 2021 earnings released: EPS US$0.91 (vs US$1.62 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$354.5m (up 45% from 2Q 2020). Net income: US$22.4m (up US$62.1m from 2Q 2020). Profit margin: 6.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Recent Insider Transactions • May 13President recently sold €382k worth of stockOn the 7th of May, Patrick Williams sold around 5k shares on-market at roughly €83.67 per share. This was the largest sale by an insider in the last 3 months. Patrick has been a seller over the last 12 months, reducing personal holdings by €928k.
Reported Earnings • May 06First quarter 2021 earnings released: EPS US$0.95 (vs US$1.35 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$339.6m (down 8.8% from 1Q 2020). Net income: US$23.4m (down 29% from 1Q 2020). Profit margin: 6.9% (down from 8.9% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • May 05Innospec Inc. Announces Semi-Annual Dividend for the First Half of 2021, Payable on May 26, 2021Innospec Inc. announced the declaration of its semi-annual dividend of $0.57 per common share for the first half of 2021, representing an increase of 10%. This dividend will be paid on May 26, 2021, to shareholders of record on May 17, 2021.
Executive Departure • May 04Senior Vice President of Corporate Development & Investor Relations Brian Watt has left the companyOn the 30th of April, Brian Watt's tenure as Senior Vice President of Corporate Development & Investor Relations ended after 3.7 years in the role. We don't have any record of a personal shareholding under Brian's name. A total of 2 executives have left over the last 12 months.
お知らせ • Mar 20Innospec Inc., Annual General Meeting, May 05, 2021Innospec Inc., Annual General Meeting, May 05, 2021, at 10:00 US Eastern Standard Time. Agenda: To consider election of two Class II Directors; to consider ratification of the election of one Class I Director; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm.
Is New 90 Day High Low • Feb 26New 90-day high: €84.00The company is up 17% from its price of €71.50 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period.
お知らせ • Feb 26Brian Watt Informs His Decision to Retire as Senior Vice President, Corporate Development and Investor Relations of Innospec Inc., Effective April 30, 2021On February 23, 2021, Mr. Brian Watt, Senior Vice President, Corporate Development and Investor Relations of Innospec Inc. (the 'Company'), informed the Company of his decision to officially retire effective April 30, 2021. The Company is discussing with Mr. Watt the possibility of him providing various support after his retirement.
Reported Earnings • Feb 19Full year 2020 earnings released: EPS US$1.17 (vs US$4.58 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$1.19b (down 21% from FY 2019). Net income: US$28.7m (down 74% from FY 2019). Profit margin: 2.4% (down from 7.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 19Revenue beats expectationsRevenue exceeded analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 9.4%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.
お知らせ • Jan 19Innospec Inc. to Report Q4, 2020 Results on Feb 16, 2021Innospec Inc. announced that they will report Q4, 2020 results After-Market on Feb 16, 2021
Valuation Update With 7 Day Price Move • Jan 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$83.00, the stock is trading at a trailing P/E ratio of 66.3x, up from the previous P/E ratio of 57.1x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 45%.
Is New 90 Day High Low • Jan 08New 90-day high: €78.00The company is up 37% from its price of €57.00 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €26.34 per share.
Is New 90 Day High Low • Dec 19New 90-day high: €73.50The company is up 30% from its price of €56.50 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.44 per share.
Valuation Update With 7 Day Price Move • Nov 26Market bids up stock over the past weekAfter last week's 17% share price gain to US$72.00, the stock is trading at a trailing P/E ratio of 57.7x, up from the previous P/E ratio of 49.3x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 24%.
Is New 90 Day High Low • Nov 16New 90-day high: €69.00The company is up 10.0% from its price of €63.00 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €130 per share.
Valuation Update With 7 Day Price Move • Nov 16Market bids up stock over the past weekAfter last week's 19% share price gain to US$69.00, the stock is trading at a trailing P/E ratio of 52.7x, up from the previous P/E ratio of 44.3x. This compares to an average P/E of 26x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 24%.
Upcoming Dividend • Nov 09Upcoming Dividend of US$0.52 Per ShareWill be paid on the 25th of November to those who are registered shareholders by the 16th of November. The trailing yield of 1.5% is below the top quartile of German dividend payers (3.8%), and is lower than industry peers (4.4%).
Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS US$0.52The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$265.1m (down 29% from 3Q 2019). Net income: US$12.7m (down 58% from 3Q 2019). Profit margin: 4.8% (down from 8.1% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 2% per year and the company’s share price has also increased by 2% per year.
Analyst Estimate Surprise Post Earnings • Nov 05Revenue misses expectationsRevenue missed analyst estimates by 4.5%. Over the next year, revenue is forecast to grow 4.6%, compared to a 2.3% growth forecast for the Chemicals industry in Germany.
お知らせ • Nov 03Innospec Inc. Appoints Elizabeth Keller Arnold as A Non-Employee DirectorInnospec Inc. announced that it has appointed Ms Elizabeth Keller Arnold as a non-employee director, effective November 1, 2020. After a long and successful career with General Electric and Tyco, Ms. Arnold was most recently Chief Financial Officer of Houghton International, a highly regarded global specialty chemical company. She is also an independent director of FreightCar America Inc. She has been appointed for an initial term until the 2021 Annual Stockholders Meeting and will also become a member of the Audit Committee.
お知らせ • Oct 08Innospec Inc. to Report Q3, 2020 Results on Nov 03, 2020Innospec Inc. announced that they will report Q3, 2020 results at 5:00 PM, GMT Standard Time on Nov 03, 2020
Is New 90 Day High Low • Sep 25New 90-day low: €53.00The company is down 18% from its price of €64.50 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €120 per share.
お知らせ • Jul 08Innospec Inc. to Report Q2, 2020 Results on Aug 04, 2020Innospec Inc. announced that they will report Q2, 2020 results at 5:00 PM, GMT Standard Time on Aug 04, 2020
